ATXI vs. CYTO, DRMA, SLRX, CMND, CNSP, SNOA, NTBL, ONCO, GLMD, and SXTP
Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Altamira Therapeutics (CYTO), Dermata Therapeutics (DRMA), Salarius Pharmaceuticals (SLRX), Clearmind Medicine (CMND), CNS Pharmaceuticals (CNSP), Sonoma Pharmaceuticals (SNOA), Notable Labs (NTBL), Onconetix (ONCO), Galmed Pharmaceuticals (GLMD), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical preparations" industry.
Altamira Therapeutics (NASDAQ:CYTO) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment.
1.9% of Altamira Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 13.0% of Altamira Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Altamira Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.
Avenue Therapeutics received 147 more outperform votes than Altamira Therapeutics when rated by MarketBeat users.
Altamira Therapeutics has higher revenue and earnings than Avenue Therapeutics.
In the previous week, Avenue Therapeutics had 4 more articles in the media than Altamira Therapeutics. MarketBeat recorded 4 mentions for Avenue Therapeutics and 0 mentions for Altamira Therapeutics. Avenue Therapeutics' average media sentiment score of 1.11 beat Altamira Therapeutics' score of 0.04 indicating that Altamira Therapeutics is being referred to more favorably in the media.
Summary
Altamira Therapeutics beats Avenue Therapeutics on 6 of the 10 factors compared between the two stocks.
Get Avenue Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avenue Therapeutics Competitors List
Related Companies and Tools
